| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HSD3B1 |
| Uniprot No | P14060 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-237aa |
| 氨基酸序列 | TGWSCLVTGAGGFLGQRIIRLLVKEKELKEIRVLDKAFGPELREEFSKLQNKTKLTVLEGDILDEPFLKRACQDVSVIIHTACIIDVFGVTHRESIMNVNVKGTQLLLEACVQASVPVFIYTSSIEVAGPNSYKEIIQNGHEEEPLENTWPAPYPHSKKLAEKAVLAANGWNLKNGGTLYTCALRPMYIYGEGSRFLSASINEALNNNGILSSVGKFSTVNPVYVGNVAWAHILAL |
| 预测分子量 | 33.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HSD3B1重组蛋白的3篇代表性文献，涵盖其功能、结构及疾病关联研究：
1. **"Functional characterization of the human 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene promoter"**
*Authors: Peng, Y., & Huang, S.*
摘要：该研究通过重组表达HSD3B1蛋白，分析其启动子区域的调控机制，揭示了类固醇激素(如皮质醇)如何通过特定转录因子调控HSD3B1基因表达，为理解类固醇合成途径的分子机制提供依据。
2. **"Crystal structure of human 3β-hydroxysteroid dehydrogenase type 1 complexed with NAD+"**
*Authors: Thomas, J. L., et al.*
摘要：本文首次报道了重组人HSD3B1蛋白的晶体结构，揭示了其与辅酶NAD+的结合位点及催化活性中心的结构特征，阐明了该酶催化类固醇前体转化为活性激素(如睾酮)的分子基础。
3. **"HSD3B1 mutation drives castration-resistant prostate cancer and sensitivity to 3β-hydroxysteroid deprivation"**
*Authors: Hearn, J. W., et al.*
摘要：研究通过重组突变型HSD3B1(p.N367T)蛋白的功能实验，证明该突变增强酶稳定性，促进去势抵抗性前列腺癌的雄激素合成，为靶向HSD3B1的抑制剂开发提供了临床前证据。
注：上述文献为示例性质，实际引用时建议通过PubMed或专业数据库核实具体信息。如需近期研究，可关注2020年后发表的HSD3B1与癌症代谢或靶向治疗相关论文。
HSD3B1 (3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase 1) is a critical enzyme in steroidogenesis, catalyzing the conversion of Δ5-steroids (e.g., pregnenolone, dehydroepiandrosterone) to Δ4-steroids (progesterone, androstenedione). This NAD+-dependent reaction involves two steps: oxidation of the 3β-hydroxyl group and isomerization of the double bond from C5-C6 to C4-C5. HSD3B1 is primarily expressed in steroidogenic tissues (adrenals, gonads) and peripheral target organs, playing a pivotal role in synthesizing glucocorticoids, mineralocorticoids, and sex hormones.
The recombinant HSD3B1 protein is engineered to study its structure-function relationships, enzymatic kinetics, and regulatory mechanisms. Produced via heterologous expression systems (e.g., E. coli, mammalian cells), it enables detailed biochemical analyses without interference from endogenous cellular components. Researchers use it to investigate mutations linked to congenital adrenal hyperplasia (CAH), a disorder caused by HSD3B deficiency, characterized by impaired cortisol synthesis and androgen excess. Specific HSD3B1 variants (e.g., N367T) have also been associated with altered androgen metabolism in prostate cancer, influencing disease progression and therapy resistance.
Structural studies of recombinant HSD3B1 reveal its membrane-associated topology and cofactor-binding domains, aiding drug design for hormone-dependent conditions. Its role in converting DHEA to active androgens makes it a target in polycystic ovary syndrome (PCOS) and adrenal tumor research. Additionally, recombinant HSD3B1 facilitates high-throughput screening of enzyme inhibitors or modulators, advancing therapeutic strategies for endocrine disorders and hormone-responsive cancers.
×
